Assembly Biosciences Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $72.3M+153.5% YoYTTM through 31 Dec 2025
Net Income -$6.1MTTM through 31 Dec 2025
Free Cash Flow -$41.2MTTM through 31 Dec 2025
Margins
| Current | |
|---|---|
| Operating Margin | -16.8% |
| Net Margin | -8.5% |
Returns
-3.0%ROE
-2.4%ROA
Balance Sheet Health
Debt / Equity0.01x
Net Debt-$245.5Mnet cash position
Cash & Equivalents$248.1M
Quality Metrics
FCF Margin-56.9%
Earnings-Beat Rate75.0%
Dividend
No dividend
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Collaboration and Licensing | $72.3M | +153.5% | View detailsGilead licensed the HPI program (ABI-5366 and ABI-1179) in late 2025, triggering a net $35 million option fee. Development plan and budget expected by mid-2026. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.